Power calculation of novel single-piece aspheric diffractive trifocal intraocular lens
<p> K.B. Pershin<sup>1</sup>, N.F. Pashinova<sup>1</sup>, M.M. Konovalova<sup>2</sup>, A.Yu.Tsygankov<sup>1</sup>, M.E. Konovalov<sup>2</sup><br> </p> <p> <sup>1</sup&g...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Prime-Media
2019-09-01
|
| Series: | РМЖ "Клиническая офтальмология" |
| Online Access: | http://clinopht.com/upload/iblock/315/315fd5dfa98f5756e5285a4bcd6f9b4b.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <p>
K.B. Pershin<sup>1</sup>, N.F. Pashinova<sup>1</sup>, M.M. Konovalova<sup>2</sup>, A.Yu.Tsygankov<sup>1</sup>, M.E. Konovalov<sup>2</sup><br>
</p>
<p>
<sup>1</sup>LLC “SovMedTech”, Moscow, Russian Federation
</p>
<p>
<sup>2</sup>LLC “Ophthalmocenter”, Moscow, Russian Federation
</p>
<p>
<i><b>Aim</b>: to analyze the efficacy of six IOL power calculation formulas for novel single-piece aspheric trifocal diffractive intraocular lens (IOL).</i>
</p>
<p>
<i><b>Patients and Methods:</b> retrospective study included 65 patients (100 eyes) with presbyopia who underwent cataract surgery or refractive lens exchange with implantation of novel multifocal IOL AcrySof PanOptix® trifocal. IOL power was calculated using six formulas, i.e., SRK/T (35%), Holladay 2 (18%), Hoffer Q (9%), Haigis (22%), and Barrett Universal II (16%). Efficacy of Barrett Universal II, Haigis, Hoffer Q, Holladay 2, Olsen, and SRK/T formulas using relevant constants was analyzed retrospectively. IOL power ranged from 13 D to 30 D.</i>
</p>
<p>
<i><b>Results</b>: optimized IOL constants were as follows: LF=2.14 for Barrett Universal II; a0=1.45, a1=0.4; a2=0.1 for Haigis; pACD = 5.71 for Hoffer Q; ACD=5.63 for Holladay 2; ACD=4.79 for Olsen; and А=119.2 for SRK/T. The lowest mean absolute error (MAE) was demonstrated for Barrett Universal II, the greatest MAEs for Holladay 2 and Hoffer Q. 67% of eyes in Barrett Universal II group, 62% of eyes in Olsen group, and more than 50% of eyes in Haigis group were within the ± 0.25 D range from the predicted refraction. Less than 50% of eyes in Hoffer Q, Holladay 2, and SRK/T groups were within the ±0.25 D range from the predicted refraction. More than 90% of eyes were within the ±1.00 D range and more than 95% of eyes were within the ±2.00 D range from the predicted refraction.</i>
</p>
<p>
<i><b>Conclusions</b>: the lowest mean absolute error and the greatest rate of target refraction achievement were in Barrett Universal II and Olsen groups. These formulas can be recommended for everyday ophthalmic practice.</i>
</p>
<p>
<i><b>Keywords</b>: cataract, phacoemulsification, trifocal IOL, IOL power calculation, constant optimization, Barrett Universal II, Olsen.</i>
</p>
<p>
<i><b>For citation: </b>Pershin K.B., Pashinova N.F., Konovalova M.M. et al. Power calculation of novel single-piece aspheric diffractive trifocal intraocular lens. Russian Journal of Clinical Ophthalmology. 2019;19(3):171–174.</i>
</p>
<i>
<p>
<b>About the authors:</b>
</p>
<p>
<i><sup>1</sup>Kirill B. Pershin — MD, PhD, Professor, Medical Director, ORCID iD 0000-0003-3445-8899;</i>
</p>
<p>
<i><sup>1</sup>Nadezhda F. Pashinova — MD, PhD, Head Doctor, ORCID iD 0000-0001-5973-0102;</i>
</p>
<p>
<i><sup>2</sup>Mariya M. Konovalova — MD, ophthalmologist, ORCID iD 0000-0003-3597-2101;</i>
</p>
<p>
<i><sup>1</sup>Alexandr Yu. Tsygankov — MD, PhD, Scientific Referent of Medical Director, ORCID iD 0000-0001-9475-3545;</i>
</p>
<p>
<i><sup>2</sup>Mikhail E. Konovalov — MD, PhD, Head Doctor, ORCID iD 0000-0002-3954-6233.</i>
</p>
<p>
<i><sup>1</sup>LLC “SovMedTech”. 3/1, Marksistskaya str., Moscow, 109147, Russian Federation.</i>
</p>
<p>
<i><sup>2</sup>LLC “Ophthalmocenter”. 56/6, 3<sup>rd</sup> Tverskaya-Yamskaya str., Moscow, 125047, Russian Federation.</i>
</p>
<p>
</p>
<p>
<i>Contact information: Alexandr Yu. Tsygankov, e-mail: <a href="mailto:alextsygankov1986@yandex.ru">alextsygankov1986@yandex.ru</a>. Financial Disclosure: no author has a financial or property interest in any material or method mentioned. There is no conflict of interests. Received 24.01.2019.</i>
</p>
</i><br> |
|---|---|
| ISSN: | 2311-7729 2619-1571 |